Substitution of a conserved amino acid residue alters the ligand binding properties of peroxisome proliferator activated receptors

被引:8
作者
Causevic, M
Wolf, CR
Palmer, CNA [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Ninewells Hosp & Med Sch, Imperial Canc Res Fund, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland
基金
英国生物技术与生命科学研究理事会;
关键词
nuclear receptor; peroxisome proliferator; fatty acid; fluorescence; thiazolidinedione; diabetes;
D O I
10.1016/S0014-5793(99)01618-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutation of glutamic acid 282 of PPAR alpha to glycine has been shown to result in an increased EC50 for a wide variety of PPAR activating compounds. This has suggested that mutant receptor has a reduced ability to bind ligand. In this study we show that this mutation reduces the affinity of mPPAR alpha and hPPAR gamma for the fluorescent fatty acid, cis-parinaric acid and that the mutant hPPAR gamma protein has:a reduced affinity for the radiolabelled compound, SB236636. These data confirm the role of this glutamic acid in ligand binding and support recent crystal structure observations regarding a proposed novel mode of ligand entry into the PPAR ligand binding cavities. (C) 1999 Federation of European Biochemical Societies.
引用
收藏
页码:205 / 210
页数:6
相关论文
共 30 条
  • [21] The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
    Ricote, M
    Li, AC
    Willson, TM
    Kelly, CJ
    Glass, CK
    [J]. NATURE, 1998, 391 (6662) : 79 - 82
  • [22] Thiazolidinediones in the treatment of insulin resistance and type II diabetes
    Saltiel, AR
    Olefsky, JM
    [J]. DIABETES, 1996, 45 (12) : 1661 - 1669
  • [23] Differentiation and reversal of malignant changes in colon cancer through PPARγ
    Sarraf, P
    Mueller, E
    Jones, D
    King, FJ
    DeAngelo, DJ
    Partridge, JB
    Holden, SA
    Chen, LB
    Singer, S
    Fletcher, C
    Spiegelman, BM
    [J]. NATURE MEDICINE, 1998, 4 (09) : 1046 - 1052
  • [24] Loss-of-function mutations in PPARγ associated with human colon cancer
    Sarraf, P
    Mueller, E
    Smith, WM
    Wright, HM
    Kum, JB
    Aaltonen, LA
    de la Chapelle, A
    Spiegelman, BM
    Eng, C
    [J]. MOLECULAR CELL, 1999, 3 (06) : 799 - 804
  • [25] SHA RS, 1993, J BIOL CHEM, V268, P7885
  • [26] ADIPOCYTE-SPECIFIC TRANSCRIPTION FACTOR-ARF6 IS A HETERODIMERIC COMPLEX OF 2 NUCLEAR HORMONE RECEPTORS, PPAR-GAMMA AND RXR-ALPHA
    TONTONOZ, P
    GRAVES, RA
    BUDAVARI, AI
    ERDJUMENTBROMAGE, H
    LUI, M
    HU, E
    TEMPST, P
    SPIEGELMAN, BM
    [J]. NUCLEIC ACIDS RESEARCH, 1994, 22 (25) : 5628 - 5634
  • [27] MPPAR-GAMMA-2 - TISSUE-SPECIFIC REGULATOR OF AN ADIPOCYTE ENHANCER
    TONTONOZ, P
    HU, E
    GRAVES, RA
    BUDAVARI, AI
    SPIEGELMAN, BM
    [J]. GENES & DEVELOPMENT, 1994, 8 (10) : 1224 - 1234
  • [28] STIMULATION OF ADIPOGENESIS IN FIBROBLASTS BY PPAR-GAMMA-2, A LIPID-ACTIVATED TRANSCRIPTION FACTOR
    TONTONOZ, P
    HU, ED
    SPIEGELMAN, BM
    [J]. CELL, 1994, 79 (07) : 1147 - 1156
  • [29] Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
    Xu, HE
    Lambert, MH
    Montana, VG
    Parks, DJ
    Blanchard, SG
    Brown, PJ
    Sternbach, DD
    Lehmann, JM
    Wisely, GB
    Willson, TM
    Kliewer, SA
    Milburn, MV
    [J]. MOLECULAR CELL, 1999, 3 (03) : 397 - 403
  • [30] Young PW, 1998, J PHARMACOL EXP THER, V284, P751